Mayo Clinic researchers recently developed an RT-PCR assay along with a break-apart FISH assay that can diagnose fibrolamellar carcinoma 100 percent of the time. The assays can detect the novel fusion at the transcriptional and genomic level, respectively.
Recent Stories for Research
Dabigatran etexilate (Pradaxa), an oral, direct thrombin inhibitor, was approved in October 2010 by the U.S. Food and Drug Administration (FDA) for prevention of stroke and thrombosis in patients with nonvalvular atrial fibrillation (AF). In a recent article in Clinical Chemistry, Mayo Clinic researchers, Hemamalini Ketha, Ph.D., and John Mills, Ph.D., discuss whether dabigatran is a risk to patient safety.
Ovarian cancer is often sensitive to platinum-based chemotherapy, causing patients to develop resistance. Oncolytic measles virus (MV) expressing the sodium iodide symporter gene (MV-NIS) facilitates localization of viral gene expression and offers a tool for tumor radiovirotherapy. Mayo Clinic researchers conducted a study in the Cancer Research journal to determine the effect of MV-NIS in patients with treatment-resistant ovarian cancer.
Other Posts for Research
- The Efficacy of Ibrutinib in the Treatment of Richter Syndrome
- The Effect of Disseminated Ureaplasma Infection on Hyperammonemia in Humans
- Assessing the Frequency of Pathogenic Alterations in Malignant Lymph Node Cytology Specimens
- Characterizing the Functional Role of IRF4 in Peripheral T-cell Lymphoma Cells
- Mayo Clinic Researchers Identify Methylated DNA Markers That May One Day Lead To Noninvasive Whole Body Cancer Screening
- Lung Cancer Study Develops New Test to Differentiate Multiple Primary Tumors from Metastasis
- Implications of Thal Amyloid Phase Across Alzheimer’s Disease
- Genetic Modifiers in Carriers of Repeat Expansions in the C9ORF72 Gene
- MALDI-TOF MS For the Diagnosis of Infectious Diseases
- Tailoring Research and Test Development to Reduce Mortality Risk of Endometrial Cancer